- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 213/86 - HydrazidesLeurs thio ou imino analogues
Détention brevets de la classe C07D 213/86
Brevets de cette classe: 55
Historique des publications depuis 10 ans
|
1
|
6
|
5
|
1
|
4
|
4
|
5
|
0
|
5
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| HMI Medical Innovations, LLC | 14 |
8 |
| The Research Foundation for The State University of New York | 1639 |
4 |
| Synta Pharmaceuticals Corp. | 174 |
3 |
| Theravance Biopharma R&D IP, LLC | 456 |
3 |
| Bayer Cropscience AG | 2009 |
2 |
| University of Florida Research Foundation, Inc. | 4052 |
2 |
| Provid Pharmaceuticals, Inc. | 14 |
2 |
| Stc.unm | 677 |
2 |
| The United States of America AS represented by The Department of Health and Human Services, Nih | 2 |
2 |
| F. Hoffmann-La Roche AG | 7947 |
1 |
| Roche Diagnostics GmbH | 2697 |
1 |
| Roche Diagnostics Operations, Inc. | 1502 |
1 |
| LG Chem, Ltd. | 17680 |
1 |
| The Regents of the University of California | 20137 |
1 |
| Syngenta Crop Protection AG | 6192 |
1 |
| The Johns Hopkins University | 5723 |
1 |
| Astellas Pharma Inc. | 1088 |
1 |
| Eurofarma Laboratorios S.A. | 37 |
1 |
| Fuji Yakuhin Co., Ltd. | 11 |
1 |
| Fundação Oswaldo Cruz - FIOCRUZ | 22 |
1 |
| Autres propriétaires | 16 |